UBS Group
NSRX

UBS Group’s Nasus Pharma NSRX Stock Holding History

UBS Group’s Portfolio NSRX Stock Details NSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,094
Closed -$6.87K – 11498
2026
Q1 		$6.87K Buy
3,094
+2,716
+719% +$14K ﹤0.01% 8644
2025
Q4 		$3.46K Sell
378
-863
-70% -$6.34K ﹤0.01% 9018
2025
Q3 		$8.25K Buy
+1,241
New +$9.99K ﹤0.01% 8672

Other funds holding NSRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's NSRX Position: Q2 2026 in Review

UBS Group sold out of Nasus Pharma (NSRX) in Q2 2026, closing a stake of 3,094 shares — an estimated $6.87K sold.

UBS Group first reported a position in NSRX in Q3 2025 and held it in 3 quarters. The position peaked at $8.25K in Q3 2025. 10 funds tracked by Wall St. Rank hold NSRX as of Q2 2026.

  • UBS Group reported no remaining Nasus Pharma position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 3,094 Nasus Pharma shares in Q2 2026, an estimated $6.87K.
  • UBS Group first reported a position in Nasus Pharma in Q3 2025 and held it in 3 quarters.
  • UBS Group's Nasus Pharma position peaked at $8.25K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Nasus Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.